| DNA methylation analysis: choosing the right method S Kurdyukov, M Bullock Biology 5 (1), 3, 2016 | 882 | 2016 |
| Multikinase inhibitors: a new option for the treatment of thyroid cancer ML Gild, M Bullock, BG Robinson, R Clifton-Bligh Nature Reviews Endocrinology 7 (10), 617-624, 2011 | 191 | 2011 |
| BRAFV600E mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer CJ O’Neill, M Bullock, A Chou, SB Sidhu, LW Delbridge, BG Robinson, ... Surgery 148 (6), 1139-1146, 2010 | 135 | 2010 |
| Utilization of a MAB for BRAFV600E detection in papillary thyroid carcinoma M Bullock, C O'Neill, A Chou, A Clarkson, T Dodds, C Toon, M Sywak, ... Endocrine-related cancer 19 (6), 779-784, 2012 | 83 | 2012 |
| Association of FOXE1 Polyalanine Repeat Region with Papillary Thyroid Cancer M Bullock, EL Duncan, C O'Neill, L Tacon, M Sywak, S Sidhu, L Delbridge, ... The Journal of Clinical Endocrinology & Metabolism 97 (9), E1814-E1819, 2012 | 80 | 2012 |
| TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas M Bullock, Y Ren, C O'Neill, A Gill, A Aniss, M Sywak, S Sidhu, ... Clinical endocrinology 85 (2), 283-290, 2016 | 78 | 2016 |
| FOXO factors and breast cancer: outfoxing endocrine resistance M Bullock Endocrine-Related Cancer 23 (2), R113-R130, 2016 | 62 | 2016 |
| Altered tear composition in smokers and patients with graves ophthalmopathy GRC Baker, M Morton, RS Rajapaska, M Bullock, S Gullu, B Mazzi, ... Archives of ophthalmology 124 (10), 1451-1456, 2006 | 56 | 2006 |
| ETS factor ETV5 activates the mutant telomerase reverse transcriptase promoter in thyroid cancer M Bullock, G Lim, Y Zhu, H Åberg, S Kurdyukov, R Clifton-Bligh Thyroid 29 (11), 1623-1633, 2019 | 41 | 2019 |
| NRASQ61R mutation-specific immunohistochemistry also identifies the HRASQ61R mutation in medullary thyroid cancer and may have a role in triaging genetic testing for MEN2 J Reagh, M Bullock, J Andrici, J Turchini, L Sioson, A Clarkson, N Watson, ... The American Journal of Surgical Pathology 41 (1), 75-81, 2017 | 32 | 2017 |
| Thyroid transcription factor FOXE1 interacts with ETS factor ELK1 to co-regulate TERT M Bullock, G Lim, C Li, IH Choi, S Kochhar, C Liddle, L Zhang, ... Oncotarget 7 (52), 85948, 2016 | 23 | 2016 |
| Contribution of a Common Variant in the Promoter of the 1-α-Hydroxylase Gene (CYP27B1) to Fracture Risk in the Elderly RJ Clifton-Bligh, TV Nguyen, A Au, M Bullock, I Cameron, R Cumming, ... Calcified tissue international 88, 109-116, 2011 | 23 | 2011 |
| Somatic Mutations of FOXE1 in Papillary Thyroid Cancer M Mond, M Bullock, Y Yao, RJ Clifton-Bligh, C Gilfillan, PJ Fuller Thyroid 25 (8), 904-910, 2015 | 20 | 2015 |
| Translational Utility of Liquid Biopsies in Thyroid Cancer Management AA Wijewardene, M Chehade, ML Gild, RJ Clifton-Bligh, M Bullock Cancers 13 (14), 3443, 2021 | 19 | 2021 |
| Medullary thyroid carcinoma: survival analysis and evaluation of mutation-specific immunohistochemistry in detection of sporadic disease S Jayakody, J Reagh, M Bullock, A Aniss, R Clifton-Bligh, D Learoyd, ... World Journal of Surgery 42, 1432-1439, 2018 | 19 | 2018 |
| Key MicroRNA’s and their targetome in adrenocortical cancer M Chehade, M Bullock, A Glover, G Hutvagner, S Sidhu Cancers 12 (8), 2198, 2020 | 18 | 2020 |
| Challenges and strategies to combat resistance mechanisms in thyroid cancer therapeutics LJ Gild, M. L., Bullock, M., Tsang, V., Clifton-Bligh, R., Robinson, B., & Wirth Thyroid, 2023 | 12 | 2023 |
| Polypharmacy with high Drug Burden Index (DBI) alters the gut microbiome overriding aging effects and is reversible with deprescribing G Gemikonakli, J Mach, F Zhang, M Bullock, T Tran, E El-Omar, SN Hilmer The Journals of Gerontology: Series A 78 (2), 213-222, 2023 | 11 | 2023 |
| An indel in phospholipase-CB-1 is linked with euthyroid multinodular goiter AD Bakhsh, I Ladas, ML Hamshere, M Bullock, G Kirov, L Zhang, ... Thyroid 28 (7), 891-901, 2018 | 11 | 2018 |
| The histamine 3 receptor is expressed in the heart and its activation opposes adverse cardiac remodeling in the angiotensin II mouse model SL McCaffrey, G Lim, M Bullock, AO Kasparian, R Clifton-Bligh, ... International journal of molecular sciences 21 (24), 9757, 2020 | 10 | 2020 |
Roderick Clifton-BlighProfessor in Endocrinology, University of SydneyE-mailová adresa ověřena na: sydney.edu.au